Thus, in our study, it was the intermediate and adverse risk AML cases which were frequently B7 positive (78.2%), as well as NPM1 mutated AML, that displayed features holding indirect evidence of an “inflammatory” microenvironment, including the expression of mainly inhibitory B7 ligands, correlated with higher percentages of CD4 effector cells, less CD4+ and CD8+ naive T cells, as well as higher ICOS and PD-1 expression. This evidence concerns the gene NPM1 and acute myeloid leukemia.